文章摘要
郭明升,马普红,靳妍霞,等.动脉粥样硬化性脑梗死二级预防药物依从性下降主观原因调查[J].安徽医药,2018,22(7):1401-1404.
动脉粥样硬化性脑梗死二级预防药物依从性下降主观原因调查
Survey on subjective reasons for decreased drug compliance of secondary prevention for atherosclerotic cerebral infarction
投稿时间:2016-11-30  
DOI:
中文关键词: 服药依从性  患者意愿  药物替代  二级预防  动脉粥样硬化  脑梗死
英文关键词: 
基金项目:
作者单位
郭明升 冀中能源峰峰集团有限公司总医院神经内科, 
马普红 冀中能源峰峰集团有限公司总医院 CT室,河北 邯郸 056200 
靳妍霞 冀中能源峰峰集团有限公司总医院神经内科, 
武华 冀中能源峰峰集团有限公司总医院药学部,河北 邯郸 056200 
李亚男 冀中能源峰峰集团有限公司总医院肾内科河北 邯郸 056200, 
杜丽霞 冀中能源峰峰集团有限公司总医院心内科,河北 邯郸 056200 
刘娟 冀中能源峰峰集团有限公司总医院神经内科, 
摘要点击次数: 2111
全文下载次数: 647
中文摘要:
      目的 调查动脉粥样硬化性脑梗死二级预防药物依从性下降的主观原因。方法 调查648例急性脑梗死患者药物依从性下降的主观原因并根据主观原因分组,比较患者的数量;根据药物种类分组,组间比较每种主观原因中患者的数量。结果 实际完成研究的患者619例(95.5%),调查结束时,药物依从性下降患者340例,经济问题(141例,41.5%)、中药替代(134例,39.4%)、指导异常(119例 35.0%)造成的患者数量均显著高于其它主观原因(P′<0.003 3)。药物种类对主观原因的重要性有影响。结论 经济问题、中药替代、指导异常是常见的主观原因。
英文摘要:
      Objective To survey on subjective reasons for decreased drug compliance of secondary prevention for patients with atherosclerotic cerebral infarction. Methods 648 patients with acute cerebral infarction were investigated. Subjective reasons for decreased drug compliance in the patient were been summarized and according to the subjective reason divided these patients into some groups. The number of the patient were compared among these groups. These patients were again divided into some groups according to the drug types. The number of patients in each subjective reason was compared among groups. Results Actually, 619 patients completed the study(95.5%) and 340 patients had decreased drug compliance at the end of the investigation. The number of patients caused by economic issues (141 patients,41. 5%) or Chinese medicine replacement (134 patients,39.4%) or unreasonable guidance (119 patients,35.0%) were all significantly higher than caused by other subjective reasons, P′<0.003 3. The importance of subjective reasons was affected by the drug category. Conclusions Economic issues, Chinese medicine replacement and unreasonable guidance are main subjective reasons for decreased drug compliance in the region.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮